News >

Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer

Published: Wednesday, Oct 19, 2016

Roman Rouzier, MD

Roman Rouzier, MD

The addition of bevacizumab (Avastin) to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer, according to results reported at the 2016 ESMO Annual Congress in Copenhagen.

“On the basis of these results, I think we can say that the adding a VEGF inhibitor to carboplatin-paclitaxel chemotherapy prior to interval debulking is safe, but there is no proof—yet, because we don’t have all the data—that the addition of a VEGF inhibitor improves the complete resection rate after interval debulking,” Vergote concluded.
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication